Vir Biotechnology (VIR) Non-Current Deffered Revenue (2018 - 2025)

Vir Biotechnology (VIR) has 8 years of Non-Current Deffered Revenue data on file, last reported at $9.4 million in Q3 2025.

• For the quarter ending Q3 2025, Non-Current Deffered Revenue changed N/A year-over-year to $9.4 million; the trailing twelve-month figure through Sep 2025 stood at $9.4 million (changed N/A YoY), and the FY2023 full-year result was $1.5 million, down 97.13% from the prior year.
• Non-Current Deffered Revenue advanced to $9.4 million in Q3 2025, from $1.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $55.5 million in Q2 2021 to a low of $1.5 million in Q4 2023.
• A 5-year average of $25.5 million and a median of $7.6 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue surged 1354.68% in 2021 and plunged 97.13% in 2023, its largest moves.
• Tracing VIR's Non-Current Deffered Revenue over 5 years: stood at $3.8 million in 2021, then soared by 1294.68% to $53.2 million in 2022, then sank by 97.13% to $1.5 million in 2023, then changed by 0.0% to $1.5 million in 2024, then soared by 518.15% to $9.4 million in 2025.
• Business Quant data shows VIR's Non-Current Deffered Revenue at $9.4 million in Q3 2025, $1.5 million in Q1 2024, and $1.5 million in Q4 2023.